| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Rudolf Uher, Benicio N Frey, Lena C Quilty, Susan Rotzinger, Pierre Blier, Jane A Foster, Daniel J Müller, Arun V Ravindran, Claudio N Soares, Gustavo Turecki, Sagar V Parikh, Roumen Milev, Glenda MacQueen, Raymond W Lam, Sidney H Kenned. Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report. The Journal of clinical psychiatry. vol 81. issue 4. 2020-09-22. PMID:32558407. |
we hypothesized that augmentation with partial dopamine agonist aripiprazole will be effective for individuals with pronounced interest-activity symptoms. |
2020-09-22 |
2023-08-13 |
Not clear |
| Qiaohui Lu, Akihiro Mouri, Yang Yang, Kazuo Kunisawa, Tomoaki Teshigawara, Mami Hirakawa, Yuko Mori, Yasuko Yamamoto, Zou Libo, Toshitaka Nabeshima, Kuniaki Sait. Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression. Behavioural brain research. vol 372. 2020-08-19. PMID:31288060. |
and aripiprazole (dopamine d |
2020-08-19 |
2023-08-13 |
mouse |
| Yam R Giri, Sachidanand R Peter. Escalation of Gambling Associated With Aripiprazole: A Case Report and Literature Review. Journal of psychiatric practice. vol 25. issue 2. 2020-06-19. PMID:30849063. |
it is postulated that aripiprazole may cause impulse-control problems because it can produce a hyperdopaminergic state in the mesolimbic pathway (reward system) through its predominant action on dopamine d3 receptors. |
2020-06-19 |
2023-08-13 |
Not clear |
| David A Kah. Commentary: Aripiprazole: The Second Wave of the Second-generation Antipsychotics. Journal of psychiatric practice. vol 25. issue 2. 2020-06-19. PMID:30849064. |
aripiprazole was the first of a subgroup of atypical antipsychotics that are mixed agonists and antagonists of dopamine, likely contributing to unusual responses in some patients. |
2020-06-19 |
2023-08-13 |
Not clear |
| Jasmina Mallet, Philip Gorwood, Yann Le Strat, Caroline Dubertre. Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review. The international journal of neuropsychopharmacology. vol 22. issue 10. 2020-05-19. PMID:31406978. |
aripiprazole, cariprazine, and brexpiprazole have partial agonism at the dopamine d2 receptor and could potentially overcome limitations associated with d2 antagonism. |
2020-05-19 |
2023-08-13 |
Not clear |
| Alexandre Lachance, Olivier Corbeil, Stéphanie Corbeil, Guillaume Chalifour, Ann-Sophie Breault, Marc-André Roy, Marie-France Demer. Case Reports of Aripiprazole and Problematic Gambling in Schizophrenia: A Critical Review of the Evidence. Journal of clinical psychopharmacology. vol 39. issue 4. 2020-02-18. PMID:31206391. |
pharmacovigilance studies have reported a higher risk of problematic gambling (pg) in people receiving aripiprazole (ari), a partial dopamine agonist. |
2020-02-18 |
2023-08-13 |
Not clear |
| Divya Gupta, Chris OʼHar. Aripiprazole Toxicity With a Biphasic Course of Somnolence. Pediatric emergency care. vol 35. issue 8. 2020-01-28. PMID:31290799. |
aripiprazole is an atypical antipsychotic with partial agonism at dopamine and serotonin receptors. |
2020-01-28 |
2023-08-13 |
Not clear |
| Ralf Kozia. [Hypersexuality Induced by Aripiprazole]. Psychiatrische Praxis. vol 47. issue 1. 2020-01-13. PMID:31284315. |
hypersexual behavior can be assumed as a rare side effect of treatment with aripiprazole and is possibly due to partial agonism on dopamine receptors or partial agonism on 5-ht |
2020-01-13 |
2023-08-13 |
Not clear |
| Guido K W Fran. Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa-A case series. The International journal of eating disorders. vol 49. issue 5. 2019-11-20. PMID:26593328. |
aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa-a case series. |
2019-11-20 |
2023-08-13 |
Not clear |
| Shunsuke Tanahashi, Satoshi Yamamura, Masanori Nakagawa, Eishi Motomura, Motohiro Okad. Corrigendum to "Dopamine D2 and serotonin 5-HT1A receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission" [Neuropharmacology 62 (2012) 765-774]. Neuropharmacology. vol 148. 2019-11-20. PMID:30733044. |
corrigendum to "dopamine d2 and serotonin 5-ht1a receptors mediate the actions of aripiprazole in mesocortical and mesoaccumbens transmission" [neuropharmacology 62 (2012) 765-774]. |
2019-11-20 |
2023-08-13 |
Not clear |
| Hui-Yi Chen, Chia-Hao Ma, Chen-Chung Li. Two Cases of De Novo Pathological Gambling Associated With Aripiprazole. Clinical neuropharmacology. vol 42. issue 3. 2019-11-01. PMID:31082834. |
aripiprazole, bearing a partial agonist activity at dopamine d2 and d3 receptors, has also been linked to such a behavioral aberration, usually on subjects predisposed with tendency of impulsive or addictive behaviors. |
2019-11-01 |
2023-08-13 |
human |
| Nobuhisa Kanahara, Makihiko Hirabayashi, Takashi Mamada, Masahiko Nishimoto, Masaomi Iy. Combination therapy of electroconvulsive therapy and aripiprazole for dopamine supersensitivity psychosis. Schizophrenia research. vol 202. 2019-10-30. PMID:29937327. |
combination therapy of electroconvulsive therapy and aripiprazole for dopamine supersensitivity psychosis. |
2019-10-30 |
2023-08-13 |
Not clear |
| Annika Frank, Dóra J Kiss, György M Keserű, Holger Star. Binding kinetics of cariprazine and aripiprazole at the dopamine D Scientific reports. vol 8. issue 1. 2019-10-25. PMID:30131592. |
binding kinetics of cariprazine and aripiprazole at the dopamine d the dissociation behaviours of aripiprazole and cariprazine at the human d |
2019-10-25 |
2023-08-13 |
human |
| Gianluca Serafini, Giulia Piccinini, Samantha Visimberga, Alice Cervetti, Martino Belvederi Murri, Fiammetta Monacelli, Maurizio Pompili, Mario Amor. Aripiprazole-induced persistent hiccup: a case report and review of the literature. Psychiatria Danubina. vol 31. issue 1. 2019-07-22. PMID:30948686. |
aripiprazole is an interesting psychoactive compound acting as a dopamine d2 partial agonist, serotonin 5-ht(1a) partial agonist and serotonin 5-ht(2a) antagonist. |
2019-07-22 |
2023-08-13 |
Not clear |
| Chen-Cheng Lin, Hsin-An Chang, Yueh-Ming Tai, Tsung-Yen Chen, Fang-Jung Wan, Chuan-Chia Chang, Che-Se Tung, Yia-Ping Li. Subchronic administration of aripiprazole improves fear extinction retrieval of Pavlovian conditioning paradigm in rats experiencing psychological trauma. Behavioural brain research. vol 362. 2019-07-11. PMID:30610908. |
the present study examined the performance of pavlovian conditioned fear and the changes of dopamine profiles following a subchronic 14-day regimen of aripiprazole (a partial agonist of dopamine d2 receptors to normalize the condition caused by dopamine imbalance) in rats previously experienced a psychologically traumatic procedure of single prolonged stress (sps). |
2019-07-11 |
2023-08-13 |
rat |
| Chen-Cheng Lin, Hsin-An Chang, Yueh-Ming Tai, Tsung-Yen Chen, Fang-Jung Wan, Chuan-Chia Chang, Che-Se Tung, Yia-Ping Li. Subchronic administration of aripiprazole improves fear extinction retrieval of Pavlovian conditioning paradigm in rats experiencing psychological trauma. Behavioural brain research. vol 362. 2019-07-11. PMID:30610908. |
the results demonstrated that aripiprazole at 5.0 mg/kg reversed the sps-impaired fear memory dysfunction and the sps-reduced dopamine efflux in the amygdala. |
2019-07-11 |
2023-08-13 |
rat |
| Piotr Janik, Natalia Szejk. Aripiprazole in treatment of Gilles de la Tourette syndrome - New therapeutic option. Neurologia i neurochirurgia polska. vol 52. issue 1. 2019-05-23. PMID:29154107. |
aripiprazole is a dopamine d2- and serotonin 5-hydroxytryptamine (5-ht) |
2019-05-23 |
2023-08-13 |
Not clear |
| b' Eva \\xc4\\x8ce\\xc5\\xa1kov\\xc3\\xa. [Current and future pharmacotherapy of severe psychiatric disorders]. Casopis lekaru ceskych. vol 157. issue 2. 2019-04-24. PMID:29790360.' |
in addition to aripiprazole two new partial dopamine agonists, brexpiprazole and cariprazine are now available. |
2019-04-24 |
2023-08-13 |
Not clear |
| Alexandre Salvador, Yulia Worbe, Cécile Delorme, Giorgio Coricelli, Raphaël Gaillard, Trevor W Robbins, Andreas Hartmann, Stefano Palminter. Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome. Scientific reports. vol 7. issue 1. 2019-04-10. PMID:28740149. |
the dopamine partial agonist aripiprazole is increasingly used to treat pathologies for which other antipsychotics are indicated because it displays fewer side effects, such as sedation and depression-like symptoms, than other dopamine receptor antagonists. |
2019-04-10 |
2023-08-13 |
human |
| Judy Hope, David Castle, Nicholas A Kek. Brexpiprazole: a new leaf on the partial dopamine agonist branch. Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists. vol 26. issue 1. 2019-04-09. PMID:29017334. |
brexpiprazole is a new dopamine partial agonist antipsychotic in the same class as aripiprazole. |
2019-04-09 |
2023-08-13 |
Not clear |